US Patent

US10940141 — Methods for the administration of certain VMAT2 inhibitors

Method of Use · Assigned to Neurocrine Biosciences Inc · Expires 2040-08-10 · 14y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a method of administering a VMAT2 inhibitor, specifically valbenazine tosylate, to a subject with severe renal impairment.

USPTO Abstract

Provided is a method of administering a vesicular monoamine transporter 2 (VMAT2) inhibitor to a subject in need thereof, wherein the subject has severe renal impairment.

Drugs covered by this patent

valbenazine-tosylate (VALBENAZINE TOSYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1995`	—	valbenazine-tosylate
`U-1995`	—	valbenazine-tosylate
`U-1995`	—	valbenazine-tosylate
`U-1995`	—	valbenazine-tosylate
`U-1995`	—	valbenazine-tosylate
`U-1995`	—	valbenazine-tosylate

Patent Metadata

Patent number: US10940141
Jurisdiction: US
Classification: Method of Use
Expires: 2040-08-10
Drug substance claim: No
Drug product claim: No
Assignee: Neurocrine Biosciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.